Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report)'s stock price was down 7.1% during trading on Monday. The stock traded as low as $17.11 and last traded at $16.8860. Approximately 447,832 shares changed hands during trading, a decline of 66% from the average daily volume of 1,301,500 shares. The stock had previously closed at $18.18.
Analyst Ratings Changes
A number of research firms have recently commented on MLYS. Zacks Research upgraded shares of Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Friday, September 11th. UBS Group initiated coverage on Mineralys Therapeutics in a research report on Sunday, October 11th. They issued a "neutral" rating and a $29.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Thursday, October 15th. HC Wainwright reissued a "buy" rating and set a $56.00 price target on shares of Mineralys Therapeutics in a research report on Monday, October 12th. Finally, Wall Street Zen downgraded Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Mineralys Therapeutics has a consensus rating of "Hold" and an average target price of $45.50.
Read Our Latest Report on Mineralys Therapeutics
Mineralys Therapeutics Price Performance
The stock has a market capitalization of $1.45 billion, a P/E ratio of -3.89 and a beta of 0.69. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. The company's 50-day simple moving average is $24.78 and its 200-day simple moving average is $27.03.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($2.30). As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current fiscal year.
Insiders Place Their Bets
In other Mineralys Therapeutics news, CEO Jon Congleton sold 75,000 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $25.46, for a total value of $1,909,500.00. Following the sale, the chief executive officer owned 528,621 shares in the company, valued at $13,458,690.66. This represents a 12.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Rodman sold 2,170 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.09, for a total value of $58,785.30. Following the completion of the sale, the insider directly owned 51,384 shares of the company's stock, valued at approximately $1,391,992.56. The trade was a 4.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 199,365 shares of company stock worth $5,461,854 in the last three months. Insiders own 18.94% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in MLYS. BlackRock Inc. bought a new position in shares of Mineralys Therapeutics in the second quarter valued at about $158,832,000. Orbimed Advisors LLC boosted its holdings in shares of Mineralys Therapeutics by 109.4% during the 1st quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company's stock worth $55,613,000 after buying an additional 1,072,500 shares during the period. Bank of America Corp DE acquired a new position in Mineralys Therapeutics in the 2nd quarter valued at about $40,620,000. Jennison Associates LLC grew its stake in Mineralys Therapeutics by 0.6% in the 1st quarter. Jennison Associates LLC now owns 1,266,174 shares of the company's stock valued at $34,301,000 after buying an additional 7,521 shares during the last quarter. Finally, Nantahala Capital Management LLC bought a new position in Mineralys Therapeutics in the 2nd quarter valued at about $22,136,577. 84.46% of the stock is owned by institutional investors and hedge funds.
Mineralys Therapeutics Company Profile
(
Get Free Report)
Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company's research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.
Mineralys' lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.